3006-19-7

Basic information

• Product Name: 6-methyl-ergoline-8-carboxylic acid methyl ester
• CAS NO: 3006-19-7
• Molecular Weight: 284.358
• Mol File: 3006-19-7.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 6-methyl-ergoline-8-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methyl-ergoline-8-carboxylic acid methyl ester(3006-19-7)
• EPA Substance Registry System: 6-methyl-ergoline-8-carboxylic acid methyl ester(3006-19-7)

Safety Data

• Hazardous Substances Data: 3006-19-7(Hazardous Substances Data)

Upstream product

• 96624-04-3 methyl 4-methyl-7-nitro-1,2,3,4,5,6-hexahydrobenzoquinoline-2-carboxylate 
• 89331-01-1 5-nitro-2-oxo-1,2,3,4-tetrahydronaphthalene 
• 4224-69-5 methyl 2-(bromomethyl)propenoate 
• 30341-92-5 #rac-ergoline-8α-carboxylic acid methyl ester 
• 82-58-6 (+/-)-lysergic acid 
• 1420013-09-7 N-(2-bromo-3-(2-methoxyvinyl)phenyl)acetamide 
• 51867-06-2 1-benzoyl-1,2,2a,3-tetrahydrobenzindol-4-(5H)-one 
• 158479-05-1 4-hydroxy-1,3,4,5-tetrahydrobenzindole 
• 1420013-23-5 N-(2-bromo-3-(2-hydroxy-5-(trimethylsilyl)pent-4-yn-1-yl)phenyl)acetamide 
• 1420013-02-0 C₁₀H₁₀BrNO₂ 
• 67-56-1 methanol 
• 2481-70-1 rac-9,10-dihydrolysergic acid 

Downstream Products

• 2481-70-1 rac-6-methyl-5α-ergoline-8β-carboxylic acid 
• 2481-70-1 rac-6-methyl-5α-ergoline-8α-carboxylic acid 
• 1752-45-0 6-methyl-5α-ergoline-8α-carboxylic acid hydrazide 
• 2481-70-1 9,10-Dihydrolysergsaeure 
• 5878-43-3 9,10-dihydrolysergic acid 
• 2481-70-1 rac-9,10-dihydrolysergic acid 
• 72821-79-5 methyl (6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylate 
• 81409-74-7 (6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid 
• 85329-86-8 (6aR,9R,10aR)-7-allyl-N-[3-(dimethylamino)propyl]-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide 
• 126554-50-5 (6aR,9R,10aR)-7-allyl-N⁹-[3-(dimethylamino)propyl]-N⁴-ethyl-N⁹-(ethylcarbamoyl)-6a,7,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9(6H)-dicarboxamide 
• 1349-51-5 rac-9,10-dihydrolysergol 
• 115-20-8 1,1,1-trichloroethanol 
• 5634-37-7 di-(2,2,2-trichloroethyl)-carbonate 
• 80993-64-2 9-methyl 7-(2,2,2-trichloroethyl) (6aR,9R,10aR)-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxylate 

Relevant articles and documents

Synthesis of novel analogs of cabergoline: Improving cardiovascular safety by removing 5-HT2B receptor agonism

The dopamine agonist cabergoline has been used to treat prolactinomas, Parkinson's disease, Cushing's disease, and sexual dysfunction. However, its clinical use was severely curtailed when it was found that patients taking cabergoline had an increased risk of developing cardiac-valve regurgitation. This potentially life-threatening condition has been associated with drugs, such as cabergoline, that are 5-HT2B receptor agonists. We prepared analogs of cabergoline and have identified several that have limited or no agonism at the 5-HT2B receptor.

ERGOLINE DERIVATIVES AS DOPAMINE RECEPTOR MODULATORS

The invention provides compounds of formula (I) wherein R1-R4 have any of the values defined in the specification, and salts thereof. The compounds are useful as dopamine receptor modulators for the treatment of diseases where modulation of dopamine receptors is implicated (e.g. sexual dysfunction, prolactinoma, Parkinson's disease, and Cushings disease).

Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst1 receptor

Non-peptidic compounds containing the octahydro-indolo[4,3-fg]quinoline (ergoline) structural element have been optimized into derivatives with high affinity (pKd r sst1 > 9) and selectivity (>1000-fold for h sst1 over h sst2-h sst5) for the somatostatin sst1 receptor. In functional assays, these ergolines act as antagonists at human recombinant sst1 receptors. Pharmacokinetic studies in rodents reveal good oral bioavailability and brain penetration for some of these compounds.